Global Coalition for Adaptive Research Announces Initiation of AZD1390 in GBM AGILE Trial Global Coalition for Adaptive Research Announces Initiation of AZD1390 in GBM AGILE Trial PR Newswire LARKSPUR ...
Expertise from Forbes Councils members, operated under license. Opinions expressed are those of the author. In today's tech-driven world, staying competitive means adapting quickly and innovating ...
AstraZeneca's AZD1390 Now Enrolling in GBM AGILE, a Registrational-Intent Phase 2/3 Adaptive Platform Trial for Patients with Glioblastoma LARKSPUR, Calif., May 13, 2025 /PRNewswire/ -- The Global ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback